Immunologic strategies for HIV-1 remission and eradication

被引：172
|
作者：
Barouch, Dan H. [1 ,2 ,3 ]
Deeks, Steven G. [4 ]
机构：
[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Ctr Virol & Vaccine Res, Boston, MA 02215 USA
[2] MIT, Massachusetts Gen Hosp, Ragon Inst, Cambridge, MA 02139 USA
[3] Harvard Univ, Cambridge, MA 02139 USA
[4] Univ Calif San Francisco, San Francisco, CA 94110 USA
来源：
SCIENCE | 2014年 / 345卷 / 6193期
关键词：
CD4(+) T-CELLS; ACTIVE ANTIRETROVIRAL THERAPY; INTERFERON-STIMULATED GENES; PERSISTENT LCMV INFECTION; PLACEBO-CONTROLLED TRIAL; HIGHLY PATHOGENIC SIV; IN-VIVO; NEUTRALIZING ANTIBODIES; ANTIVIRAL THERAPY; RHESUS-MONKEYS;
D O I：
10.1126/science.1255512
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Antiretroviral therapy (ART) is able to suppress HIV-1 replication indefinitely in individuals who have access to these medications, are able to tolerate these drugs, and are motivated to take them daily for life. However, ART is not curative. HIV-1 persists indefinitely during ART as quiescent integrated DNA within memory CD4(+) T cells and perhaps other long-lived cellular reservoirs. In this Review, we discuss the role of the immune system in the establishment and maintenance of the latent HIV-1 reservoir. A detailed understanding of how the host immune system shapes the size and distribution of the viral reservoir should lead to the development of a new generation of immune-based therapeutics, which may eventually contribute to a curative intervention.
引用
收藏
页码：169 / 174
页数：6
相关论文
共 50 条
  • [41] An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction
    Reid, W
    Sadowska, M
    Denaro, F
    Rao, S
    Foulke, J
    Hayes, N
    Jones, O
    Doodnauth, D
    Davis, H
    Sill, A
    O'Driscoll, P
    Huso, D
    Fouts, T
    Lewis, G
    Hill, M
    Kamin-Lewis, R
    Wei, C
    Ray, P
    Gallo, RC
    Reitz, M
    Bryant, J
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (16) : 9271 - 9276
  • [42] Immunologic strategies to cure HIV infection
    Chomont, N.
    ANTIVIRAL THERAPY, 2013, 18 : A4 - A4
  • [43] Association of race and gender with HIV-1 RNA levels and immunologic progression
    Anastos, K
    Gange, SJ
    Lau, B
    Weiser, B
    Detels, R
    Giorgi, JV
    Margolick, JB
    Cohen, M
    Phair, J
    Melnick, S
    Rinaldo, CR
    Kovacs, A
    Levine, A
    Landesman, S
    Young, M
    Muñoz, A
    Greenblatt, RM
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2000, 24 (03) : 218 - 226
  • [44] Early immunologic and virologic predictors of clinical HIV-1 disease progression
    Mahnke, Yolanda D.
    Song, Kaimei
    Sauer, Mariana M.
    Nason, Martha C.
    Giret, Maria Teresa M.
    Carvalho, Karina I.
    Costa, Priscilla R.
    Roederer, Mario
    Kallas, Esper G.
    AIDS, 2013, 27 (05) : 697 - 706
  • [45] Immunologic and viral markers of HIV-1 disease progression: Implications for dentistry
    Patton, LL
    Shugars, DC
    JOURNAL OF THE AMERICAN DENTAL ASSOCIATION, 1999, 130 (09): : 1313 - 1322
  • [46] Immunologic nonresponders and T-regulatory cells in HIV-1 infection
    Suy, Florence
    Botelho-Nevers, Elisabeth
    Gagneux-Brunon, Amandine
    Fresard, Anne
    Paul, Stephane
    Lambert, Claude
    Pozzetto, Bruno
    Lucht, Frederic
    AIDS, 2013, 27 (18) : 2968 - 2971
  • [47] Treatment interruption as a tool to measure changes in immunologic response to HIV-1
    Kutzler, Michele A.
    Jacobson, Jeffrey M.
    CURRENT OPINION IN HIV AND AIDS, 2008, 3 (02) : 131 - 135
  • [48] Epidemiology of discordant virologic and immunologic responses in HIV-1 infected patients
    Thiébaut, R
    Lewden, C
    Chêne, G
    MEDECINE ET MALADIES INFECTIEUSES, 2005, 35 : S31 - S32
  • [49] Intimate Relations: Molecular and Immunologic Interactions BetweenNeisseria gonorrhoeaeand HIV-1
    Guvenc, Furkan
    Kaul, Rupert
    Gray-Owen, Scott D.
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [50] Structural and immunologic correlates of chemically stabilized HIV-1 envelope glycoproteins
    Schiffner, Torben
    Pallesen, Jesper
    Russell, Rebecca A.
    Dodd, Jonathan
    de Val, Natalia
    LaBranche, Celia C.
    Montefiori, David
    Tomaras, Georgia D.
    Shen, Xiaoying
    Harris, Scarlett L.
    Moghaddam, Amin E.
    Kalyuzhniy, Oleksandr
    Sanders, Rogier W.
    McCoy, Laura E.
    Moore, John P.
    Ward, Andrew B.
    Sattentau, Quentin J.
    PLOS PATHOGENS, 2018, 14 (05)
12345